PATENT CLAIM ANALYSIS

Application Number: 15564531
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-05
Patent Classification: ["514", "629000"]

Abstract:
The present invention relates to methods and compositions for treating heart failure in a subject using histone deacetylase (HDAC) inhibitors and/or histone acetyltransferases (HAT) activators.

Claim (Index 32):
The method of  claim 28 , wherein the cyclic tetrapeptide is a trapoxin, romidepsin, HC-toxin, chlamydocin, diheteropeptin, WF-3161, Cyl-1, Cyl-2, apicidin, depsipeptide (FK228), FR225497, FR901375, a spiruchostatin, a salinamide, a cyclic-hydroxamic-acid-containing peptide, and/or any derivative thereof or combination thereof.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 88.0
- Lexical Diversity: 1.11111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11365268', '14777211', '14884827', '14650473', '12851610']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7417090686517147
- 35 USC 102 Novelty (BERT): 0.5317142082392557
- Combined Prediction Score: 0.7207095826104688
- Mean Citation Score: 264.59926
- Max Citation Score: 313.5870700000001
- Similarity Product: 196.8042029149092

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test